Parvovirus B19 is a small DNA virus. Infection with parvovirus B19 during pregnancy may cause serious complications in the fetus, including hydrops fetalis and fetal death. The purpose of the present study is to clarify the clinical manifestations and outcomes of parvovirus B19 infection during pregnancy. This prospective study enrolled 478 women with suspected B19 infections during pregnancy between 1999 and 2004. One hundred cases (21%) of B19 infection were detected in 478 pregnant women who had been exposed to B19. Serological infection was confirmed by measurement of B19-specific IgM and IgG in sera. Forty-nine cases reported maternal clinical symptoms and 51 cases were asymptomatic. Facial rash was the most common symptom, with 51% (25/49) of the symptomatic patients complaining of either a facial, body or limb rash. The most common infectious source was children living in the home. Overall, the incidence of adverse fetal effects (including hydrops fetalis and fetal death) related to intrauterine B19 infection was 7% (7/100), and all seven cases were exposed to B19 infection before 20 weeks of gestation. Although half of the cases with parvovirus B19 infections during pregnancy were asymptomatic, patients with adverse fetal effects tended to be symptomatic including rash and fever. These clinical data may supply useful information to produce clinical guidelines for managing B19 infection during pregnancy. parvovirus B19; pregnancy; clinical manifestation; hydrops fetalis; fetal outcome
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Human parvovirus B19 (B19) was first identified in the sera of normal blood bank donors being screened for the hepatitis B virus (Cossart et al. 1975) . It was subsequently shown to be the causative agent of several diseases in humans, including the common childhood illness erythema infectiosum, transient aplastic crises associated with hemolytic anemias, chronic bone marrow failure occurring in subjects with immunodeficiency, and some cases of non-immune hydrops fetalis (NIHF) and intrauterine fetal death (Brown et al. 1984; Anderson et al. 1985; Brown and Young 1995; Yaegashi et al. 1999a; Chisaka et al. 2003) . Aplastic crisis is the direct result of erythroid lineage progenitor cells being infected with B19 and undergoing apoptosis in response to the viral protein, NS1 (Yaegashi et al. 1989; Moffatt et al. 1998; Chisaka et al. 2002) . Fetuses infected during the hepatic stage of hematopoiesis are particularly susceptible because of the short half life of their red blood cells (Levy et al. 1997; Yaegashi et al. 1998) . Infectious parvovirus B19 particles were produced in erythroid progenitor cells of the hepatic stage, called productive infection, which may also contribute to the severity of hyporegenerative anemia of the fetus (Yaegashi 2000) .
Prospective studies have estimated the incidence of hydrops fetalis or fetal death secondary to B19 infection to be 2-24% (Yaegashi et al. 1999b) , with the highest rate of fetal complications seen if infection occurs in the first 20 weeks of gestation (Miller et al. 1998; Enders et al. 2004) . Retrospective studies have shown B19 infection to be responsible for 10-50% of cases of hydrops fetalis, in which the etiology was unknown . Two reports have proposed management plans for pregnant women exposed to individuals with B19 infection and for women shown to be infected upon serological testing (Levy et al. 1997; Schild et al. 1999) . These studies, however, showed some discrepancies, and further study is necessary in order to establish clinical practice guidelines. An additional complication is that many cases infected with B19 during pregnancy are asymptomatic and have no reason to suspect that they have contracted B19 infection (Harger et al. 1998; Searle et al. 1998) .
In order to gain a better understanding of the presentation, outcomes, and epidemiology of B19 infection, the following clinical questions need to be answered. First, what percentage of pregnant women exposed to B19 actually becomes infected? Second, are the clinical signs and symptoms of B19 infection in pregnant women similar to those in non-pregnant women or those in children? Third, do asymptomatic pregnant women have the same incidence of fetal loss as symptomatic cases? Finally, where are most infections contracted: in the home, at work, or elsewhere ?
Over a period of six years, we prospectively surveyed pregnant women in Miyagi prefecture, Japan, who might have been infected with B19. This report describes the incidence and clinical manifestations of maternal B19 infection and pregnancy outcomes, and briefly addresses the epidemiology of B19 infection in pregnant women.
PATIENTS AND METHODS
The study population consisted of pregnant women in Miyagi prefecture, Japan with suspected exposure to B19 infection. The population of the Miyagi prefecture is approximately two million. Between 1999 and 2004, there were approximately 22,000 births per year in the prefecture, and all 78 maternal clinics in the prefecture were requested to participate in this project by the Miyagi prefecture government. Inclusion criteria were contact during pregnancy with an individual with a known or suspected B19 infection, or the complaint of clinical symptoms indicative of B19 infection, including facial rash, flu-like illness, or arthralgia. Informed consent was obtained from each patient. Two 1-ml blood samples were taken 2 weeks apart to confirm the maternal infection with her pair-serum samples. During the study period, 874 serum specimens were collected from 478 pregnant women; 478 samples were collected at the first sampling and 396 samples at the second sampling. In the remaining 82 cases, the second sample was not collected because of the patients' refusal. Serum antibodies specific to B19 capsid proteins were detected by enzyme-linked immunosorbent assay (ELISA) for anti-B19 specific IgM and IgG as previously described .
Clinical information including the gestational week when the women had contact with an infectious source, the place where the women came into contact with an infectious source, the date of onset of maternal symptoms if present, and the estimated date of confinement were recorded on a clinical card and sent to the Tohoku University Hospital along with the first serum sample. Lists of symptoms such as facial rash, body rash, limb rash, fever, runny nose, cough, joint pain, general fatigue, and lymphadenopathy were printed on the clinical card to standardize the selection and reporting of maternal symptoms. If the patient could not recall the date of viral
RESULTS
Among 478 pregnant women enrolled, 100 cases were confirmed to be infected with B19 virus by the detection of B19-specific IgM. The percentage of serologically confirmed cases in women suspected of contracting a B19 infection during pregnancy was 21% (100/478). In these 100 cases, 66 were IgM positive in both of the paired-sera, 11 were IgM positive only in the first serum, and 8 were IgM negative in the first sample and positive in the second serum. For the remaining 15 cases, the first sera were positive for B19-specific IgM, but the second sample was not collected. All 100 cases were singleton pregnancies.
Forty-nine cases (49%) reported clinical maternal symptoms and 51 cases (51%) were asymptomatic. Facial rash was the most common symptom, with 51% (25/49) of the symptomatic patients complaining of either a facial, body or limb rash. Fever, joint pain, and general fatigue were reported in 15-20% of all infected patients (Fig. 1) . The most common infectious source among the 100 cases was children in the home (65%) ( Table 1 ). Child's friend, the workplace, daycare, and hospital were also important sources of infection (Table 1) .
Among the 100 cases with maternal B19 infection, two cases were lost to follow-up, one exposure, the time of maternal infection was defined as one week before the date of onset of maternal symptoms. Gestational weeks were estimated by the last menstrual period and modified when necessary using fetal growth measurements obtained with ultrasonography. Maternal B19 infection was confirmed by the detection of B19-specific IgM and the women positive for anti-B19 IgM were registered as cases for the prospective follow-up study. Care of the women enrolled in the follow-up portion of the study was transferred to the Tohoku University Hospital. The patients were monitored with weekly serial ultrasounds for twelve weeks after the date of viral exposure or the date of the onset of symptoms. Hydrops fetalis was diagnosed when the accumulation of fluid in body cavities and subcutaneous edema were evident on ultrasound. After the twelve-week follow-up period, all patients with normal maternal and fetal findings were returned to their original clinics for follow up and delivery. Questionnaires addressing pregnancy progress and outcomes were sent to maternal clinics within two months after the estimated date of confinement.
Since 1981, the Miyagi prefecture government has monitored the number of cases of erythema infectiosum each month through a network of 70 pediatric clinics. These data were used to identify outbreaks of erythema infectiosum in the Miyagi prefecture.
The data were compared with Fisher's exact test, and differences with a p value of < 0.05 were considered statistically significant. Fig. 1 . Symptoms in pregnant women with B19 infection during pregnancy.
Self reported symptoms of B19 infection during pregnancy. Facial rash was the most common symptom. Fever, joint pain, and general fatigue were reported in 15-20% of all infected patients. relocated, and the other was lost for unknown reasons. One case had an early abortion at 9 weeks of gestation. Eighty seven cases had term live births. The mean birth weight of the infants was 3,132 ± 44 g. These women progressed normally through pregnancy and no abnormalities were noted in the babies. Characteristics of cases with adverse fetal effects were summarized in Table 2 . Two cases (cases 9 and 10) had preterm live deliveries at 32 weeks of gestation and 24 weeks of gestation, respectively. One case (case 8) was a still birth at 22 weeks of gestation of an infant with surface anomalies and a trisomy 13 karyotype. It is unlikely that this pregnancy loss was the direct consequence of B19 intrauterine infection. The remaining seven cases consisted of either fetal losses after 12 weeks of gestation, a hydropic appearance of the fetus or intrauterine fetal death without fetal anomalies. All seven cases were s e r o l o g i c a l l y n e g a t i v e f o r t h e T O R C H (Toxoplasma, Rubella virus, Cytomegalo virus, Herpes simplex virus) syndrome. Immunologic problems such as isoimmunization due to Rhesus blood group incompatibility, ABO blood group incompatibility, or other blood group incompatibilities were also absent in these cases.
Overall, the incidence of adverse effects related to intrauterine B19 infection was 7% (7/100), which was much higher than in normal pregnancy, where the incidence is around 1% (Maternal and Child Health Division, Children and Families Bureau 2004). Five of the above cases were intrauterine fetal death and the remaining two were live birth after spontaneous recov- ery. The risk of adverse effects seemed dependent on the week of gestation when maternal infection took place. All seven cases were exposed to B19 infection before 20 weeks of gestation (Table 3) . Regarding the association between maternal clinical symptoms and fetal adverse effects, the incidence of adverse fetal effects in patients with clinical symptoms seemed higher than in patients without clinical symptoms (Table 3 ). The difference in incidences between these two groups, however, was not statistically significant (Fisher's exact test, p = 0.25).
Monthly monitoring of the number of cases of erythema infectiosum identified two outbreaks of the disease during the study period. The first was from the spring of 2001 through the summer We found that six of the seven cases of hydrops fetalis or fetal loss clustered during these outbreaks: six during the first outbreak and one during the second outbreak (Fig. 2) .
DISCUSSION
We examined 874 sera from 478 pregnant women who were suspected to be exposed to B19 infection during pregnancy. We serologically confirmed 100 cases of B19 infection; namely 21% of pregnant women exposed to B19 actually became infected. Our data underscored the importance of testing paired sera because 8 cases out of 85 cases with paired sera were positive in only one B19-IgM test. Second, this study has shown that the most common symptom of B19 infection in pregnant women is facial rash. Therefore, the clinical signs and symptoms of B19 infection in pregnant women are similar to those in children, where the most common symptom is also facial rash (Kelly et al. 1999) . Third, patients with adverse fetal effects tended to be symptomatic including rash and fever.
Finally, the most common infectious source was children living in the home.
In terms of clinical symptoms, a previous study showed that rash was more common in children than in adults (90% vs 50%), while fatigue and joint pain were more common in adults (Kelly et al. 1999) . In the present study, facial and limb rashes were the most common symptom, with joint pain being less common. The clinical manifestation of B19 infection in pregnant women is different from that in non-pregnant women and more closely resembled B19 infections in children. Previous reports have shown 30-60% of maternal B19 infection to be entirely asymptomatic (Harger et al. 1998; Searle et al. 1998) , which is in good agreement with our finding of 51% of patients being asymptomatic. In view of the association between symptoms and fetal complications, two small studies have suggested that the risk of fetal loss and hydrops may be greater in asymptomatic women (Sillis et al. 1994; Smoleniec et al. 1994) . It is possible that there are both qualitative and quantitative differences in the immune response of asymptomatic women because the rash and arthralgia in B19 infection are immune mediated. On the other hand, Enders et al. (2004) have reported that there was no association between the presence of maternal symptoms and the incidence of non-hydropic fetal death or hydrops fetalis, although the presence of rash and/or arthropathy between 9 and 16 weeks of gestation was associated with an increased risk of non-hydropic fetal death. In this study, patients with adverse fetal effects tended to be symptomatic including rash and fever, which is consistent with the data of Enders et al. (2004) . However, larger studies are needed to better outline the prevalence of infection and to clarify the role of the maternal immune response in the pathogenesis of B19 infection.
The present study is of clinical significance from an epidemiological standpoint and a formidable challenge to infection prevention. The most common infectious source was children living in the home. It is, however, unrealistic to isolate a mother from her children. Thus, the best hope for infection prevention lies in the development of a vaccine.
Our prospective study has shown that 7% of pregnancies with B19 infections resulted in fetal loss, which is much higher than the incidence of fetal loss in normal pregnancy in Japan. This rate of adverse fetal outcome is similar to rates of 5 to 10%, previously reported from other countries (Miller et al. 1998; Searle et al. 1998; Enders et al. 2004 ). This study also indicates that the week of gestation, when the patient was infected, is an important determinant of adverse fetal outcome. The rate of fetal loss is higher among women infected before 20 weeks of gestation than after 20 weeks (Miller et al. 1998; Yaegashi et al. 1999b; Enders et al. 2004 ). These studies and our previous data confirmed that hydrops fetalis caused by B19 infection occurrs at greater frequencies during epidemic periods than non-epidemic periods. This suggests that it may be beneficial to monitor pregnant women for B19 intrauterine infection during outbreaks of erythema infectiosum. Finally, given the potential for developmen-tal delay in infants born following intrauterine infection (Rodis et al. 1998) , long term follow-up of the infants born in this study will be required.
